References

112 distinct sources, deduplicated across compounds. Sources are restricted to regulators, legislation, pharmacopoeias, trial registries, peer-reviewed journals and compound developers. Vendor sites, retailers, blogs, encyclopedias, citation aggregators and preprint servers are excluded by policy, and that restriction is enforced when the content is built rather than left to editorial discipline.

  1. A hydrogen peroxide-free enzymatic cycling assay for NAD and NADH quantification — PLOS, PLOS One, 2012 · PMID 23091632Cited by NAD+ · accessed 2026-07-30
  2. A multimodal HPLC stability indicating approach for the estimation of semaglutide and tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma — Springer, BMC Chemistry, 2026 · doi:10.1186/s13065-025-01716-7Cited by Semaglutide, Tirzepatide · accessed 2026-07-30
  3. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+ — Frontiers, Frontiers in Aging Neuroscience, 2019 · PMID 31572171Cited by NAD+ · accessed 2026-07-30
  4. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects — Oxford University Press, American Journal of Clinical Nutrition, 2018 · PMID 29992272Cited by NAD+ · accessed 2026-07-30
  5. Agency Response Letter, GRAS Notice No. GRN 000635, nicotinamide riboside chloride — US Food and Drug Administration, 2016Cited by NAD+ · accessed 2026-07-30
  6. Agenda, CHMP meeting 18-21 May 2026 (EMA/CHMP/93949/2026) — European Medicines Agency, 2026Cited by Orforglipron · accessed 2026-07-30
  7. ALANYLHISTIDYLLYSINE — Global Substance Registration System record, UNII 1AVY5QO8WR — US Food and Drug Administration, 2026Cited by AHK-Cu · accessed 2026-07-30
  8. Assessment report — Mounjaro (tirzepatide), EMA/791310/2022 — European Medicines Agency, 2022Cited by Tirzepatide · accessed 2026-07-30
  9. Assessment report — Ozempic (semaglutide), EMA/CHMP/715701/2017 — European Medicines Agency, 2017Cited by Semaglutide · accessed 2026-07-30
  10. Assessment report — Rybelsus (semaglutide), EMA/95374/2020 — European Medicines Agency, 2020Cited by Semaglutide · accessed 2026-07-30
  11. Assessment report — Wegovy (semaglutide), EMA/112307/2022 — European Medicines Agency, 2022Cited by Semaglutide · accessed 2026-07-30
  12. Characterization of low-level D-amino acid isomeric impurities of semaglutide using liquid chromatography-high resolution tandem mass spectrometry — Elsevier, Journal of Pharmaceutical and Biomedical Analysis, 2023 · doi:10.1016/j.jpba.2022.115164 · PMID 36462248Cited by Semaglutide · accessed 2026-07-30
  13. Chugai and Lilly enter into a license agreement for oral GLP-1 agonist, OWL833 — Chugai Pharmaceutical, 2018Cited by Orforglipron · accessed 2026-07-30
  14. Commission Implementing Regulation (EU) 2020/16 of 10 January 2020 authorising the placing on the market of nicotinamide riboside chloride as a novel food — EUR-Lex, 2020Cited by NAD+ · accessed 2026-07-30
  15. Commission Implementing Regulation (EU) 2022/1160 of 5 July 2022 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use and the specifications of the novel food nicotinamide riboside chloride — EUR-Lex, 2022Cited by NAD+ · accessed 2026-07-30
  16. Consolidated Regulation (EC) No 1223/2009 on cosmetic products, consolidated text of 1 May 2026 — EUR-Lex, 2026Cited by GHK-Cu, AHK-Cu · accessed 2026-07-31
  17. Consolidated Union list of novel foods, Commission Implementing Regulation (EU) 2017/2470, consolidated to 14 July 2026 — EUR-Lex, 2026Cited by NAD+ · accessed 2026-07-30
  18. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity — Elsevier, Biochimica et Biophysica Acta, 2001 · doi:10.1016/s0304-4165(01)00127-1 · PMID 11325542Cited by GHK-Cu · accessed 2026-07-30
  19. CosIng ingredient record, COPPER TRIPEPTIDE-1 — European Commission, 2026Cited by GHK-Cu · accessed 2026-08-05
  20. CosIng ingredient record, TRIPEPTIDE-3 — European Commission, 2026Cited by AHK-Cu · accessed 2026-07-31
  21. CosIng ingredient records, COPPER TRIPEPTIDE-34 and COPPER TRIPEPTIDE-34 HCL — European Commission, 2026Cited by AHK-Cu · accessed 2026-08-05
  22. Dietary Supplements list of monographs prioritized for development — United States Pharmacopeia, 2026Cited by NAD+ · accessed 2026-07-30
  23. DISODIUM NICOTINAMIDE ADENINE DINUCLEOTIDE, reduced — Global Substance Registration System record, UNII 8295030YNC — US Food and Drug Administration, 2026Cited by NAD+ · accessed 2026-07-30
  24. Drugs@FDA application records for semaglutide: NDA 209637, NDA 213182, NDA 215256, NDA 218316 and ANDA 220314 — US Food and Drug Administration, 2026Cited by Semaglutide · accessed 2026-08-05
  25. Drugs@FDA application records for tirzepatide: NDA 215866 (Mounjaro) and NDA 217806 (Zepbound) — US Food and Drug Administration, 2026Cited by Tirzepatide · accessed 2026-08-05
  26. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS — Elsevier, European Journal of Pharmaceutics and Biopharmaceutics, 2025 · doi:10.1016/j.ejpb.2025.114780 · PMID 40490042Cited by Semaglutide · accessed 2026-07-30
  27. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial — Elsevier, eClinicalMedicine, 2025 · doi:10.1016/j.eclinm.2025.103633Cited by NAD+ · accessed 2026-07-30
  28. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin — American Medical Association, Archives of Facial Plastic Surgery, 2006 · doi:10.1001/archfaci.8.4.252 · PMID 16847171Cited by GHK-Cu · accessed 2026-07-30
  29. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials — Taylor and Francis, Critical Reviews in Food Science and Nutrition, 2025 · PMID 39116016Cited by NAD+ · accessed 2026-07-30
  30. EU Novel Food Status Catalogue — European Commission, 2026Cited by NAD+ · accessed 2026-07-30
  31. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+) — Elsevier, Journal of Investigative Dermatology, 2000 · doi:10.1046/j.1523-1747.2000.00166.x · PMID 11121126Cited by GHK-Cu · accessed 2026-07-30
  32. Extension of use of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 — European Food Safety Authority, EFSA Journal, 2021 · doi:10.2903/j.efsa.2021.6843 · PMID 34804232Cited by NAD+ · accessed 2026-07-30
  33. FDA and FTC Warning Letter, Alive By Nature Inc., MARCS-CMS 607435 — US Food and Drug Administration, 2020Cited by NAD+ · accessed 2026-07-30
  34. FDA approves first new molecular entity under National Priority Voucher program — US Food and Drug Administration, 2026Cited by Orforglipron · accessed 2026-07-30
  35. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for chronic weight management — Eli Lilly and Company, 2026Cited by Orforglipron · accessed 2026-07-30
  36. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, 8-9 May 2017 — nicotinamide adenine dinucleotide review and nomination — US Food and Drug Administration, 2017Cited by NAD+ · accessed 2026-07-30
  37. FDA reminds compounders to use ingredients suitable for sterile compounding — US Food and Drug Administration, 2024Cited by NAD+ · accessed 2026-07-30
  38. FDA Response to Citizen Petition, Docket FDA-2023-P-0872, regarding the regulatory status of beta-nicotinamide mononucleotide — US Food and Drug Administration, 2025Cited by NAD+ · accessed 2026-07-30
  39. FDA Response to Citizen Petition, Docket FDA-2023-P-1867, Council for Responsible Nutrition — US Food and Drug Administration, 2025Cited by NAD+ · accessed 2026-07-30
  40. FDA Warning Letter, GenoGenix LLC, MARCS-CMS 718739 — US Food and Drug Administration, 2026Cited by NAD+ · accessed 2026-07-30
  41. FDA Warning Letter, MARCS-CMS 695663 — US Food and Drug Administration, 2024Cited by Retatrutide · accessed 2026-07-30
  42. FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration, 2026Cited by Retatrutide · accessed 2026-07-30
  43. First oral GLP-1 treatment for weight management — European Medicines Agency, 2026Cited by Semaglutide · accessed 2026-07-30
  44. FOUNDAYO (orforglipron) tablets, for oral use — prescribing information — US Food and Drug Administration, 2026Cited by Orforglipron · accessed 2026-07-30
  45. FSA Register of Novel Food Authorisations, entry NOVEL-96 nicotinamide riboside chloride — Food Standards Agency, 2026Cited by NAD+ · accessed 2026-07-30
  46. Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro — Oxford University Press, Metallomics, 2024 · doi:10.1093/mtomcs/mfae019Cited by GHK-Cu · accessed 2026-07-30
  47. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy — Springer, Inflammation Research, 2010 · doi:10.1007/s00011-010-0214-4Cited by GHK-Cu · accessed 2026-07-30
  48. Influence of buffering capacity, pH, and temperature on the stability of semaglutide: a preformulation study — Wiley, Journal of Peptide Science, 2025 · doi:10.1002/psc.70039 · PMID 40635175Cited by Semaglutide · accessed 2026-07-30
  49. Intermediate Cu(II)-thiolate species in the reduction of Cu(II)GHK by glutathione: a handy chelate for biological Cu(II) reduction — American Chemical Society, Inorganic Chemistry, 2021 · doi:10.1021/acs.inorgchem.1c02669Cited by GHK-Cu · accessed 2026-07-30
  50. Intravenous infusion of nicotinamide adenine dinucleotide versus nicotinamide riboside: a retrospective tolerability pilot study in a real-world setting — Frontiers, Frontiers in Aging, 2026 · PMID 41704678Cited by NAD+ · accessed 2026-07-30
  51. Lilly’s triple agonist retatrutide: successful results from two additional studies — Eli Lilly and Company, 2026Cited by Retatrutide · accessed 2026-07-30
  52. Liposomes as carriers of GHK-Cu tripeptide for cosmetic application — MDPI, Pharmaceutics, 2023 · doi:10.3390/pharmaceutics15102485Cited by GHK-Cu · accessed 2026-07-30
  53. Long-term stability of nicotinamide cofactors in common aqueous buffers — MDPI, Molecules, 2024 · doi:10.3390/molecules29225453Cited by NAD+ · accessed 2026-07-30
  54. Meeting highlights from the Committee for Medicinal Products for Human Use, 20-23 July 2026 — European Medicines Agency, 2026Cited by Orforglipron · accessed 2026-07-30
  55. Metabolism and chemical degradation of new antidiabetic drugs: a review of analytical approaches for analysis of glutides and gliflozins — MDPI, Biomedicines, 2023 · doi:10.3390/biomedicines11082127Cited by Semaglutide · accessed 2026-07-30
  56. MHRA products database search result for orforglipron — Medicines and Healthcare products Regulatory Agency, 2026Cited by Orforglipron · accessed 2026-07-30
  57. MHRA products database search result for retatrutide — Medicines and Healthcare products Regulatory Agency, 2026Cited by Retatrutide · accessed 2026-07-30
  58. MHRA products database, semaglutide summaries of product characteristics — Medicines and Healthcare products Regulatory Agency, 2026Cited by Semaglutide · accessed 2026-07-30
  59. MHRA products database, tirzepatide summaries of product characteristics — Medicines and Healthcare products Regulatory Agency, 2026Cited by Tirzepatide · accessed 2026-07-30
  60. Molar absorptivities of beta-NADH and beta-NAD at 260 nm — Oxford University Press, Clinical Chemistry, 1975 · PMID 165910Cited by NAD+ · accessed 2026-07-30
  61. MOUNJARO (tirzepatide) injection, for subcutaneous use — US prescribing information — Eli Lilly and Company, via DailyMed (US National Library of Medicine), 2026Cited by Tirzepatide · accessed 2026-08-05
  62. Mounjaro EPAR product information, Annex I summary of product characteristics — European Medicines Agency, 2026Cited by Tirzepatide · accessed 2026-07-30
  63. N.m.r. and e.p.r. investigation of the interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma — Portland Press, Biochemical Journal, 1983 · PMID 6318731Cited by GHK-Cu · accessed 2026-07-30
  64. NAD hydrolysis: chemical and enzymatic mechanisms — Springer, Molecular and Cellular Biochemistry, 1994 · PMID 7898470Cited by NAD+ · accessed 2026-07-30
  65. NAD metabolome analysis in human cells using 1H NMR spectroscopy — MDPI, International Journal of Molecular Sciences, 2018 · doi:10.3390/ijms19123906Cited by NAD+ · accessed 2026-07-30
  66. NAD, NAD+, NADH or NMN medicines sold in Australia — safety alert — Therapeutic Goods Administration, 2026Cited by NAD+ · accessed 2026-07-30
  67. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence — Elsevier, Ageing Research Reviews, 2026 · doi:10.1016/j.arr.2026.103057 · PMID 41655607Cited by NAD+ · accessed 2026-07-30
  68. NADIDE — Global Substance Registration System record, UNII 0U46U6E8UK — US Food and Drug Administration, 2026Cited by NAD+ · accessed 2026-07-30
  69. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men — Wiley, The Journal of Physiology, 2020 · PMID 31710095Cited by NAD+ · accessed 2026-07-30
  70. Novel applications of CE-ICP-MS/MS: monitoring of antiaging GHK-Cu cosmetic component encapsulation in liposomes — Wiley, Electrophoresis, 2024 · doi:10.1002/elps.202400047 · PMID 39451062Cited by GHK-Cu · accessed 2026-07-30
  71. ORFORGLIPRON — Global Substance Registration System record, UNII 7ZW40D021M — US Food and Drug Administration, 2026Cited by Orforglipron · accessed 2026-07-30
  72. ORFORGLIPRON CALCIUM — Global Substance Registration System record, UNII VI5M9OZV2X — US Food and Drug Administration, 2026Cited by Orforglipron · accessed 2026-07-30
  73. Orforglipron: First Approval — Springer, Drugs, 2026 · doi:10.1007/s40265-026-02363-5Cited by Orforglipron · accessed 2026-07-30
  74. Overview of Short Peptides for Hair Loss — MDPI, Biomedicines, 2026 · doi:10.3390/biomedicines14040864Cited by AHK-Cu · accessed 2026-07-30
  75. Ozempic EPAR product information, Annex I summary of product characteristics — European Medicines Agency, 2026Cited by Semaglutide · accessed 2026-07-30
  76. Peptide mapping analysis of synthetic semaglutide and liraglutide for generic development of drugs originating from recombinant DNA technology — Elsevier, Journal of Pharmaceutical and Biomedical Analysis, 2025 · doi:10.1016/j.jpba.2025.116682 · PMID 39847923Cited by Semaglutide · accessed 2026-07-30
  77. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery — Taylor and Francis, Pharmaceutical Development and Technology, 2016 · doi:10.3109/10837450.2014.979944 · PMID 25384620Cited by GHK-Cu · accessed 2026-07-30
  78. PREZATIDE — Global Substance Registration System record, UNII 39TG2H631E — US Food and Drug Administration, 2026Cited by GHK-Cu · accessed 2026-07-30
  79. PREZATIDE COPPER — Global Substance Registration System record, UNII 6BJQ43T1I9 — US Food and Drug Administration, 2026Cited by GHK-Cu · accessed 2026-07-30
  80. Quantifying the cellular NAD+ metabolome using a tandem liquid chromatography mass spectrometry approach — Springer, Metabolomics, 2018 · doi:10.1007/s11306-017-1310-zCited by NAD+ · accessed 2026-07-30
  81. RASFF notification 2024.3096 — unauthorised novel food NMN in food supplements, sales ban and market withdrawal — European Commission, 2024Cited by NAD+ · accessed 2026-07-30
  82. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data — MDPI, International Journal of Molecular Sciences, 2018 · doi:10.3390/ijms19071987Cited by GHK-Cu · accessed 2026-07-30
  83. Regulation (EC) No 1223/2009 on cosmetic products, as assimilated law applying in Great Britain — UK Statute Law Database, 2026Cited by GHK-Cu, AHK-Cu · accessed 2026-07-31
  84. Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain — Office for Product Safety and Standards, 2026Cited by GHK-Cu, AHK-Cu · accessed 2026-07-31
  85. RETATRUTIDE — Global Substance Registration System record, UNII NOP2Y096GV — US Food and Drug Administration, 2026Cited by Retatrutide · accessed 2026-07-30
  86. Review of incretin receptor pharmacology including orforglipron receptor agonism — MDPI, International Journal of Molecular Sciences, 2026 · doi:10.3390/ijms27031409Cited by Orforglipron · accessed 2026-07-30
  87. Rybelsus EPAR product information, Annex I summary of product characteristics — European Medicines Agency, 2026Cited by Semaglutide · accessed 2026-07-30
  88. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults — Springer Nature, Scientific Reports, 2019 · PMID 31278280Cited by NAD+ · accessed 2026-07-30
  89. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics — SAGE Publishing, International Journal of Toxicology, 2018 · doi:10.1177/1091581818807863Cited by GHK-Cu · accessed 2026-07-30
  90. Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics — Final Report — Cosmetic Ingredient Review, 2014Cited by GHK-Cu, AHK-Cu · accessed 2026-07-30
  91. Safety of beta-nicotinamide mononucleotide pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC — European Food Safety Authority, EFSA Journal, 2026 · doi:10.2903/j.efsa.2026.10007 · PMID 42125559Cited by NAD+ · accessed 2026-07-30
  92. SEMAGLUTIDE — Global Substance Registration System record, UNII 53AXN4NNHX — Global Substance Registration System (NIH/NCATS), 2026Cited by Semaglutide · accessed 2026-08-05
  93. Semaglutide aggregates into oligomeric micelles and short fibrils in aqueous solution — American Chemical Society, Biomacromolecules, 2025 · doi:10.1021/acs.biomac.5c00342Cited by Semaglutide · accessed 2026-07-30
  94. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides — Elsevier, Analytical Biochemistry, 1987 · PMID 2829656Cited by NAD+ · accessed 2026-07-30
  95. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ — Elsevier, FEBS Letters, 1988 · doi:10.1016/0014-5793(88)80509-X · PMID 3169264Cited by GHK-Cu · accessed 2026-07-30
  96. Swissmedic warning regarding GLP-1 products — Swissmedic, 2025Cited by Retatrutide · accessed 2026-07-30
  97. Ternary Cu(II) complex with GHK peptide and cis-urocanic acid as a potential physiologically functional copper chelate — MDPI, International Journal of Molecular Sciences, 2020 · doi:10.3390/ijms21176190Cited by GHK-Cu · accessed 2026-07-30
  98. The Cosmetic Products Enforcement Regulations 2013 (S.I. 2013/1478) — UK Statute Law Database, 2013Cited by GHK-Cu, AHK-Cu · accessed 2026-07-31
  99. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis — Wiley, Journal of Cachexia, Sarcopenia and Muscle, 2025 · PMID 40275690Cited by NAD+ · accessed 2026-07-30
  100. The effect of tripeptide-copper complex on human hair growth in vitro — Springer, Archives of Pharmacal Research, 2007 · doi:10.1007/BF02978833 · PMID 17703734Cited by AHK-Cu · accessed 2026-07-30
  101. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial — Springer, GeroScience, 2023 · doi:10.1007/s11357-022-00705-1 · PMID 36482258Cited by NAD+ · accessed 2026-07-30
  102. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma — Portland Press, Biochemical Journal, 1981 · PMID 7340824Cited by GHK-Cu · accessed 2026-07-30
  103. Thermally stressed solid-state stability of semaglutide: understanding the influence of temperature on protein content, secondary structure, phase transition, and chemical degradation — Springer, Pharmaceutical Research, 2026 · doi:10.1007/s11095-026-04094-4 · PMID 42086873Cited by Semaglutide · accessed 2026-07-30
  104. Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry with the weaker competitor glycine — Springer, Journal of Biological Inorganic Chemistry, 2012 · doi:10.1007/s00775-011-0824-5 · PMID 21898044Cited by GHK-Cu · accessed 2026-07-30
  105. Think twice about injecting peptides bought online — unauthorized products can seriously harm — Health Canada, 2026Cited by Retatrutide · accessed 2026-07-30
  106. TIRZEPATIDE — Global Substance Registration System record, UNII OYN3CCI6QE — Global Substance Registration System (NIH/NCATS), 2026Cited by Tirzepatide · accessed 2026-08-05
  107. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products — Therapeutic Goods Administration, 2026Cited by Retatrutide · accessed 2026-07-30
  108. WEGOVY (semaglutide) injection, for subcutaneous use, and WEGOVY (semaglutide) tablets, for oral use — US prescribing information — Novo Nordisk, via DailyMed (US National Library of Medicine), 2026Cited by Semaglutide · accessed 2026-08-05
  109. Wegovy EPAR product information, Annex I summary of product characteristics — European Medicines Agency, 2026Cited by Semaglutide · accessed 2026-07-30
  110. WHO Drug Information Vol. 36, No. 4, 2022 — Proposed INN: List 128 — World Health Organization, 2022Cited by Retatrutide · accessed 2026-07-30
  111. X-ray and solution structures of Cu(II)GHK and Cu(II)DAHK complexes: influence on their redox properties — Wiley, Chemistry - A European Journal, 2011 · doi:10.1002/chem.201100751 · PMID 21780203Cited by GHK-Cu · accessed 2026-07-30
  112. ZEPBOUND (tirzepatide) injection, for subcutaneous use — US prescribing information — Eli Lilly and Company, via DailyMed (US National Library of Medicine), 2026Cited by Tirzepatide · accessed 2026-08-05

Back to the knowledge base